🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Linvoseltamab

    Regeneron UK Limited

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  2. Lisocabtagene maraleucel

    Celgene Europe Limited

    Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  3. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  4. Lomustine "medac" 40 mg, Fibromun

    Philogen S.p.A.

    Glioblastoma

    phase 2 small molecule active

    1 trial

  5. Loncastuximab Tesirine

    ADC Therapeutics SA

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    4 trials

  6. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed or Refractory Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Loncastuximab tesirine

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma Refractory

    phase 2 small molecule completed

    1 trial

  8. Lonsurf 15 mg/6.14 mg film-coated tablets, IRINOTECAN, Bemarituzumab, PACLITAXEL, RAMUCIRUMAB

    The George Institute

    FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction

    phase 2 small molecule active

    1 trial

  9. Loratadina NORMON 10 mg Comprimidos EFG

    The George Institute

    Effect of loratadine in patients with lymphangioleiomyomatosis

    phase 2 small molecule active

    1 trial

  10. Losartan Potassium

    Ultragenyx UK Limited

    Eosinophilic Esophagitis

    phase 2 small molecule completed

    1 trial

  11. Lotilaner Gel, 2.0%

    Tarsus Pharmaceuticals

    Papulopustular Rosacea

    phase 2 small molecule completed

    1 trial

  12. Low-dose ASA

    Atrium Therapeutics

    Germ Cell Tumor

    phase 2 small molecule active

    1 trial

  13. Lumevoq

    GenSight Biologics S.A.

    Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene

    phase 2 small molecule active

    1 trial

  14. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Extensive-stage Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  16. Lutathera 370 MBq/mL solution for infusion, LysaKare 25 g/25 g solution for infusion

    The George Institute

    Neuroendocrine tumor

    phase 2 small molecule active

    1 trial

  17. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  18. Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions

    phase 2 small molecule active

    1 trial

  19. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Verona Pharma Ireland Limited

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial

  20. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Fondazione Telethon ETS

    recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

    phase 2 small molecule active

    1 trial

  21. LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas

    phase 2 small molecule active

    1 trial

  22. Lytgobi 4 mg film-coated tablets, 5-FU medac 50 mg/ml, Injektionslösung, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tevimbra 100 mg concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  23. M5049 low dose

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  24. MCC-135

    Takeda

    Congestive Heart Failure

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources